Volume 16, Issue 12, Pages (December 2008)

Slides:



Advertisements
Similar presentations
Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Advertisements

Volume 3, Issue 5, Pages (May 2001)
Volume 23, Issue 1, Pages (January 2015)
Volume 23, Issue 4, Pages (April 2015)
Adeno-associated Virus Serotype Vectors Efficiently Transduce Normal Prostate Tissue and Prostate Cancer Cells  Jianzhong Ai, Dan Wang, Qiang Wei, Hong.
Brian Dall Schyth, Niels Lorenzen, Finn Skou Pedersen 
Supplementary Figure I
Volume 22, Issue 8, Pages (August 2014)
Volume 13, Issue 6, Pages (June 2006)
Volume 14, Issue 1, Pages (July 2006)
Volume 16, Issue 3, Pages (March 2008)
Long-Term Rescue of a Lethal Inherited Disease by Adeno-Associated Virus–Mediated Gene Transfer in a Mouse Model of Molybdenum-Cofactor Deficiency  S.
Volume 17, Issue 7, Pages (July 2009)
Volume 19, Issue 4, Pages (April 2011)
Volume 22, Issue 12, Pages (December 2014)
Intraspinal AAV Injections Immediately Rostral to a Thoracic Spinal Cord Injury Site Efficiently Transduces Neurons in Spinal Cord and Brain  Michelle.
Volume 13, Issue 1, Pages (January 2006)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 12, Pages (December 2010)
Volume 15, Issue 2, Pages (February 2007)
Volume 20, Issue 3, Pages (March 2012)
Volume 16, Issue 3, Pages (March 2008)
Molecular Therapy - Methods & Clinical Development
Oral Administration of Recombinant Adeno-associated Virus-mediated Bone Morphogenetic Protein-7 Suppresses CCl4-induced Hepatic Fibrosis in Mice  Zhi-Ming.
Volume 19, Issue 11, Pages (November 2011)
Xiaoyin Xu, Zhong Yang, Qiang Liu, Yaming Wang  Molecular Therapy 
Volume 23, Issue 12, Pages (December 2015)
Volume 22, Issue 10, Pages (October 2014)
Volume 15, Issue 2, Pages (February 2007)
Volume 18, Issue 4, Pages (April 2010)
Volume 22, Issue 8, Pages (August 2014)
Molecular Therapy - Nucleic Acids
Volume 24, Issue 9, Pages (September 2016)
Volume 22, Issue 5, Pages (May 2014)
Volume 19, Issue 3, Pages (March 2011)
Volume 24, Issue 7, Pages (July 2016)
Volume 18, Issue 1, Pages (January 2010)
Volume 23, Issue 10, Pages (October 2015)
Adenovirus Virion Stability and the Viral Genome: Size Matters
Volume 6, Issue 1, Pages (July 2002)
Volume 18, Issue 1, Pages (January 2010)
Volume 16, Issue 6, Pages (June 2008)
Computer-assisted Hydrodynamic Gene Delivery
Volume 17, Issue 2, Pages (February 2009)
Volume 19, Issue 6, Pages (June 2011)
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
The Effect of Size and Shape of RNA Nanoparticles on Biodistribution
Volume 17, Issue 12, Pages (December 2009)
Volume 13, Issue 3, Pages (March 2006)
Volume 23, Issue 12, Pages (December 2015)
Volume 19, Issue 6, Pages (June 2011)
Volume 18, Issue 3, Pages (March 2010)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Kasey L Jackson, Robert D Dayton, Ronald L Klein 
Volume 24, Issue 10, Pages (October 2016)
Volume 18, Issue 12, Pages (December 2010)
Maria P Limberis, Christie L Bell, Jack Heath, James M Wilson 
Volume 15, Issue 7, Pages (July 2007)
Volume 24, Issue 2, Pages (February 2016)
Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice  Haiyan Fu, Kim Zaraspe, Naoko.
Volume 24, Issue 1, Pages (January 2016)
Volume 23, Issue 3, Pages (March 2015)
Volume 24, Issue 1, Pages (January 2016)
Volume 19, Issue 5, Pages (May 2011)
Volume 21, Issue 1, Pages (January 2013)
Volume 18, Issue 7, Pages (July 2010)
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Volume 3, Issue 5, Pages (May 2001)
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Volume 16, Issue 12, Pages 1953-1959 (December 2008) Percutaneous Transendocardial Delivery of Self-complementary Adeno-associated Virus 6 Achieves Global Cardiac Gene Transfer in Canines  Lawrence T Bish, Meg M Sleeper, Benjamin Brainard, Stephen Cole, Nicholas Russell, Elanor Withnall, Jason Arndt, Caryn Reynolds, Ellen Davison, Julio Sanmiguel, Di Wu, Guangping Gao, James M Wilson, H Lee Sweeney  Molecular Therapy  Volume 16, Issue 12, Pages 1953-1959 (December 2008) DOI: 10.1038/mt.2008.202 Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 1 Delivery of single-stranded adeno-associated virus 9 (ssAAV9) and self-complementary AAV9 (scAAV9) to the canine heart via needle-tip injection catheter. (a) For analysis, the heart was divided into four equal sections through the short axis from base to apex. Green fluorescent protein (GFP) expression in representative cryosections of the heart 7–10 days after injection of either (b) 2 × 1013 genome copies (gc)/kg of ssAAV9-CB-EGFP or (c) 5 × 1011 gc/kg of scAAV9-CB-EGFP. Endo, endocardium; Epi, epicardium; IVS, interventricular septum; LVFW, left ventricular free wall. Bar = 200 µm. Quantitative analysis of GFP expression reported as either (d) total area positive for GFP or (e) percent cardiomyocyte area positive for GFP. Note that scAAV9 is superior to ssAAV9 even at a 40-fold lower dose (*P = 0.001). Error bars represent mean ± SD. Molecular Therapy 2008 16, 1953-1959DOI: (10.1038/mt.2008.202) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 2 Delivery of self-complementary adeno-associated virus 8 (scAAV8) and scAAV6 to the canine heart via needle-tip injection catheter. Green fluorescent protein (GFP) expression in representative cryosections of the heart 7–10 days following injection of either 5 × 1011 gc/kg of (a) scAAV8-CB-EGFP or (b) scAAV6-CB-EGFP. Endo, endocardium; Epi, epicardium; IVS, interventricular septum; LVFW, left ventricular free wall. Bar = 200 µm. Quantitative analysis of GFP expression reported as either (c) total area positive for GFP or (d) percent cardiomyocyte area positive for GFP. Note that scAAV6 is superior to the other serotypes examined (*P = 0.0001). Error bars represent mean ± SD. Molecular Therapy 2008 16, 1953-1959DOI: (10.1038/mt.2008.202) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions

Figure 3 Biodistribution of adeno-associated virus (AAV) vectors 7–10 days after delivery to the canine heart via needle-tip injection catheter. (a) Biodistribution in several organs examined. Go, gonad; He, heart; Ki, kidney; Li, liver; Lu, lung; SM, skeletal muscle; Sp, spleen; St, stomach. (b) Tissue tropism of vectors evaluated reported as ratio of vector detected in heart to vector detected in organ of choice. Note that self-complementary AAV6 (scAAV6) is highly tropic for cardiac tissue when compared with the other vectors. (c) GFP expression in cryosections of the liver 7–10 days after treatment. Bar = 40 µm. (d) Quantitative analysis of GFP expression in liver. Note that there are significantly fewer positive cells in the scAAV6 group compared with other scAAV serotypes (*P = 0.002). HPF (high power field) (×40). Error bars represent mean ± SD. Molecular Therapy 2008 16, 1953-1959DOI: (10.1038/mt.2008.202) Copyright © 2008 The American Society of Gene Therapy Terms and Conditions